Paul Noble, MD

This issue highlights discussions on the latest published clinical trials (ASCEND, INPULSIS, and PANTHER) and includes a forum to share your opinions and learn how they compare with your colleagues. NOTE: iOS users, for best viewing use iBooks.

Paul Noble, MD (Chair); Harold R. Collard, MD; Vincent Cottin, MD, PhD; Sonye K. Danoff, MD, PhD; David J. Lederer, MD, MS; Luca Richeldi, MD, PhD

Begin

CME/CE Information

Activity Title PILOT Connect (August)
Topic Idiopathic Pulmonary Fibrosis
Accreditation Type AMA PRA Category 1 Credits
Release Date August 2014
Expiration Date August 31, 2015 - No longer available for credit
Estimated Time to Complete Activity 60 minutes

LEARNING OBJECTIVES

Upon completion of the activity, participants should be able to:

  • Summarize the current understanding of the IPF disease process and strategies that can help measure disease progression and treatment response.
  • Evaluate clinical trial data on available and emerging treatments for IPF.

ACTIVITY FACULTY

Harold R. Collard, MD
Associate Professor of Medicine
Director, Interstitial Lung Disease Program
University of California, San Francisco
San Francisco, California

Vincent Cottin, MD, PhD
Respiratory Physician
National Reference Center for Rare Pulmonary Diseases
Lyon, France

Sonye K. Danoff, MD, PhD
Associate Professor of Medicine
Johns Hopkins Medicine
Baltimore, Maryland

David J. Lederer, MD, MS
Herbert Irving Assistant Professor of Medicine and Epidemiology (in Pediatrics)
Associate Medical Director, Lung Transplant Program
Co-Director, Interstitial Lung Disease Program
Columbia University Medical Center / New York Presbyterian Hospital
New York, New York

Paul W. Noble, MD
Chair, Department of Medicine
Director, Women’s Guild Lung Institute
Cedars-Sinai Medical Center
Los Angeles, California

Luca Richeldi, MD, PhD
Professor of Respiratory Medicine
Chair of Interstitial Lung Disease
University of Southampton
Southampton, United Kingdom

METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT

  1. There are no fees for participating in and receiving credit for this activity.
  2. Review the activity objectives and CME/CE information.
  3. Complete the CME/CE activity.
  4. Complete the posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  5. Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  6. Your CME/CE certificate will be available for download.

CLICK HERE TO VIEW TECHNICAL REQUIREMENTS

SPONSOR

This activity is sponsored by The France Foundation.

tff-logo250x43

TARGET AUDIENCE

This activity is intended for pulmonologists, surgeons, critical care clinicians, pharmacists, advanced practice nurses, and other health care professionals involved in the management of patients with IPF.

STATEMENT OF NEED

Idiopathic pulmonary fibrosis (IPF) is characterized by progressive worsening of dyspnea and lung function and is associated with a poor prognosis. Today, median survival time from diagnosis is two to five years in patients with IPF. In 2011 an international committee of the American Thoracic Society (ATS) and European Respiratory Society (ERS) published updated guidelines for the diagnosis and management of patients with IPF. In spite of the existence of these guidelines, several considerations still present challenges for health care providers in regard to the management of patients with IPF. These include the optimal management of acute exacerbations and the treatment of comorbid conditions commonly seen in patients with IPF. Recent publication of clinical results presents exciting prospects for patients. Practitioners should be familiar with these results in anticipation of FDA action on emerging drugs.

ACCREDITATION STATEMENT

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

Physicians
The France Foundation designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

RESOLUTION OF CONFLICTS OF INTEREST

In accordance with the ACCME Standards for Commercial Support of CME, The France Foundation will implement mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity.

DISCLOSURES

It is the policy of The France Foundation to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity have disclosed to the participants any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The France Foundation has identified and resolved any and all conflicts of interest prior to the release of this activity.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures

The following faculty has indicated he has relationships with industry to disclose relative to the content of this CME activity:

  • Harold R. Collard, MD has received grants/research support from Boehringer Ingelheim, Genentech, NHLBI, and UCSF. He has served as a consultant for Bayer, Biogen Idec, FibroGen, Gilead, InterMune, Mesoblast, Moerae Matrix, Pfizer, Promedior, and Takeda.
  • Vincent Cottin, MD, PhD has served as a consultant for Bayer, Boehringer Ingelheim, Gilead, GlaxoSmithKine, InterMune, and Roche. He has received honoraria from Actelion, Boehringer Ingelheim, and InterMune.
  • Sonye K. Danoff, MD, PhD has served as a consultant for Boehringer Ingelheim and InterMune.
  • David Lederer, MD, MS has served as a consultant for Gilead, InterMune, and Immuneworks.
  • Paul W. Noble, MD has served as a consultant for Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, InterMune, Moerae Matrix, Roche, and Takeda.
  • Luca Richeldi, MD, PhD has received grants/research support from Boehringer Ingelheim and InterMune, and has served as a consultant for Biogen Idec, Boehringer Ingelheim, ImmuneWorks, InterMune, MedImmune, Roche, Sanofi-Aventis, and Takeda. He has received honoraria from Shionogi.

UNAPPROVED USE DISCLOSURE

The France Foundation requires CME faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

COMMERCIAL SUPPORT ACKNOWLEDGMENT

This activity is supported by an educational grant from Boehringer Ingelheim and InterMune.

DISCLAIMER

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, Boehringer Ingelheim, and InterMune assume no liability for the information herein.

COPYRIGHT INFORMATION

Copyright © 2014 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

  • The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
  • Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.

PRIVACY POLICY

The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundation's Privacy Policy can be viewed at http://www.francefoundation.com/privacy.

CONTACT INFORMATION

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or This email address is being protected from spambots. You need JavaScript enabled to view it..

 

Begin

Access other Therapeutic Areas: